VRTX · News · 20261104N

Guidance and Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-11-04 · Importance 62 · Surprise 60

Vertex raised its full-year revenue guidance, setting the top end at $13.25 billion. The report does not specify the revised lower end of the guidance range or quantify the increase. No further timeframe for the full-year outlook is stated.